AANA June 2021 Journal Course: Harnessing the Endocannabinoid System: What it Means for the Anesthesia Provider (ME)

Start Course Now

Class A Credits: 1.0

Format: Video

Course Launch Date: 6/1/21

Course Expires: 5/31/24

Currently the endocannabinoid system is rarely considered with an anesthetic purpose in mind. Several new categories of drug development may soon change that. Anesthesia providers will become acquainted with the endocannabinoid system, and be able to anticipate the possible impact of new anesthetic adjuncts which are formulated to manipulate endocannabinoid levels. 

The American Association of Nurse Anesthesiology is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

AANA is an approved provider by the California Board of Registered Nursing, CEP #10862.

Post-Test Attempt Notice
A minimum passing score of 80% is required to pass this course. You have TWO opportunities to achieve a passing score. If you fail to achieve a passing score of 80%, you will not receive CE credit for this course.

Content Disclaimer:

The views, information, or opinions expressed within the videos and audio are solely those of the individuals involved and do not necessarily represent those of the American Association of Nurse Anesthesiology.

Course content has been prepared by the presenter/developer, and each viewer agrees that the presenter/developer is solely responsible for the content and the accuracy thereof. The viewer agrees that the American Association of Nurse Anesthesiology has no responsibility or liability for the accuracy or completeness of the content.

Disclosure Statement:

All presenters and planners of this CNE activity are required to disclose to the audience any significant financial relationship with the manufacturer(s) of any commercial products, goods, or services related to patient care. If any conflict has been disclosed, the planners of this program assure that the content is unbiased and free of any conflicts of interest. All planners, authors, and content reviewers disclosed there were no commercial interest relationships to declare.

  • Describe the endocannabinoid system its components and their mechanisms of action.
  • Discuss past and present utilization of the endocannabinoid system for analgesia and anesthesia.
  • Discuss the types of conditions being explored for treatment by pharmacological endocannabinoid manipulation.
  • Examine barriers to development of drugs that enhance the endocannabinoid system.
  • Discuss concerns regarding neuroplasticity of the EC system due to longterm activation.

Brandy Flanagan, RN, BSN, SRNA